Abstract | BACKGROUND:
Immunotherapy targeting PD-1/PD-L1 fails to induce clinical responses in most patients with solid cancers. N-803, formerly ALT-803, is an IL-15 superagonist mutant and dimeric IL-15RαSushi-Fc fusion protein complex that enhances CD8+ T and NK cell expansion and function and exhibits anti- tumor efficacy in preclinical models. Previous in vitro studies have shown that IL-15 increases PD-L1 expression, a negative regulator of CD8+ T and NK cell function. Most reported preclinical studies administered N-803 intraperitoneally not subcutaneously, the current clinical route of administration. N-803 is now being evaluated clinically in combination with PD-1/ PD-L1 inhibitors. However, the mechanism of action has not been fully elucidated. Here, we examined the anti- tumor efficacy and immunomodulatory effects of combining N-803 with an anti-PD-L1 antibody in preclinical models of solid carcinomas refractory to anti-PD-L1 or N-803. METHODS: Subcutaneous N-803 and an anti-PD-L1 monoclonal antibody were administered as monotherapy or in combination to 4T1 triple negative breast and MC38-CEA colon tumor-bearing mice. Anti- tumor efficacy was evaluated, and a comprehensive analysis of the immune-mediated effects of each therapy was performed on the primary tumor, lung as a site of metastasis, and spleen. RESULTS: We demonstrate that N-803 treatment increased PD-L1 expression on immune cells in vivo, supporting the combination of N-803 and anti-PD-L1. N-803 plus anti-PD-L1 was well-tolerated, reduced 4T1 lung metastasis and MC38-CEA tumor burden, and increased survival as compared to N-803 and anti-PD-L1 monotherapies. Efficacy of the combination therapy was dependent on both CD8+ T and NK cells and was associated with increased numbers of these activated immune cells in the lung and spleen. Most alterations to NK and CD8+ T cell phenotype and number were driven by N-803. However, the addition of anti-PD-L1 to N-803 significantly enhanced CD8+ T cell effector function versus N-803 and anti-PD-L1 monotherapies, as indicated by increased Granzyme B and IFNγ production, at the site of metastasis and in the periphery. Increased CD8+ T cell effector function correlated with higher serum IFNγ levels, without related toxicities, and enhanced anti- tumor efficacy of the N-803 plus anti-PD-L1 combination versus either monotherapy. CONCLUSIONS: We provide novel insight into the mechanism of action of N-803 plus anti-PD-L1 combination and offer preclinical proof of concept supporting clinical use of N-803 in combination with checkpoint inhibitors, including for patients non- and/or minimally responsive to either monotherapy.
|
Authors | Karin M Knudson, Kristin C Hicks, Sarah Alter, Jeffrey Schlom, Sofia R Gameiro |
Journal | Journal for immunotherapy of cancer
(J Immunother Cancer)
Vol. 7
Issue 1
Pg. 82
(03 21 2019)
ISSN: 2051-1426 [Electronic] England |
PMID | 30898149
(Publication Type: Journal Article, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- ALT-803
- Antibodies, Monoclonal
- B7-H1 Antigen
- Proteins
- Recombinant Fusion Proteins
|
Topics |
- Animals
- Antibodies, Monoclonal
(administration & dosage, pharmacology)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, pharmacology)
- B7-H1 Antigen
(antagonists & inhibitors)
- CD8-Positive T-Lymphocytes
- Cell Line, Tumor
- Colonic Neoplasms
(drug therapy, immunology)
- Drug Synergism
- Female
- Humans
- Injections, Subcutaneous
- Killer Cells, Natural
(drug effects)
- Mice
- Proteins
(administration & dosage, pharmacology)
- Recombinant Fusion Proteins
- Treatment Outcome
- Triple Negative Breast Neoplasms
(drug therapy, immunology)
- Xenograft Model Antitumor Assays
|